Vice Provost and Dean of Research


Showing 1,741-1,750 of 1,760 Results

  • Roham Zamanian

    Roham Zamanian

    James and Yvonne Wood Professor of Pulmonary Vascular Medicine

    Current Research and Scholarly Interests1. Development and evaluation of prognostic and diagnostic integral biomarkers in PAH.

    2. Prevalence and Treatment of Insulin Resistance in PAH.

    3. Role of inflammation and proteomic signature in PAH

    4. Development of novel therapeutics (bench to bedside) including FK506 & Elastase Inhibition in PAH.

    5. Assessment of Vasoreactivity (gain and loss) in pulmonary arterial hypertension

    6. Assessment of microvascular function in PAH.

  • Richard Zare

    Richard Zare

    Marguerite Blake Wilbur Professor of Natural Science and Professor, by courtesy, of Physics

    Current Research and Scholarly InterestsMy research group is exploring a variety of topics that range from the basic understanding of chemical reaction dynamics to the nature of the chemical contents of single cells.

    Under thermal conditions nature seems to hide the details of how elementary reactions occur through a series of averages over reagent velocity, internal energy, impact parameter, and orientation. To discover the effects of these variables on reactivity, it is necessary to carry out studies of chemical reactions far from equilibrium in which the states of the reactants are more sharply restricted and can be varied in a controlled manner. My research group is attempting to meet this tough experimental challenge through a number of laser techniques that prepare reactants in specific quantum states and probe the quantum state distributions of the resulting products. It is our belief that such state-to-state information gives the deepest insight into the forces that operate in the breaking of old bonds and the making of new ones.

    Space does not permit a full description of these projects, and I earnestly invite correspondence. The following examples are representative:

    The simplest of all neutral bimolecular reactions is the exchange reaction H H2 -> H2 H. We are studying this system and various isotopic cousins using a tunable UV laser pulse to photodissociate HBr (DBr) and hence create fast H (D) atoms of known translational energy in the presence of H2 and/or D2 and using a laser multiphoton ionization time-of-flight mass spectrometer to detect the nascent molecular products in a quantum-state-specific manner by means of an imaging technique. It is expected that these product state distributions will provide a key test of the adequacy of various advanced theoretical schemes for modeling this reaction.

    Analytical efforts involve the use of capillary zone electrophoresis, two-step laser desorption laser multiphoton ionization mass spectrometry, cavity ring-down spectroscopy, and Hadamard transform time-of-flight mass spectrometry. We believe these methods can revolutionize trace analysis, particularly of biomolecules in cells.

  • Christopher K. Zarins

    Christopher K. Zarins

    Walter Clifford Chidester and Elsa Rooney Chidester Professor of Surgery, Emeritus

    Current Research and Scholarly InterestsDiagnosis of coronary artery disease using coronary CT angiography with AI-enabled quantitation of coronary plaque burden and lesion-specific coronary ischemia is used to guide management of CAD. Applying this strategy to PAD patients with no cardiac symptoms reveals a high prevalence of silent coronary ischemia. Ischemia-targeted coronary revascularization may to reduce death and MI and improve long-term survival. Randomized trials in carotid and peripheral vascular patients are underway .

  • James L. Zehnder, M.D.

    James L. Zehnder, M.D.

    Professor of Pathology (Research) and of Medicine (Hematology)

    Current Research and Scholarly InterestsMy main research and clinical interests include molecular pathogenesis of acquired cytopenias, genetic testing for inherited non-malignant hematologic disorders, next-generation sequencing approaches to T and B cell clonality testing, somatic mutations in cancer and assessment of minimal residual disease in cancer patients.

  • Michael Zeineh

    Michael Zeineh

    Professor of Radiology (Neuroimaging and Neurointervention)

    BioDr. Michael Zeineh received a B.S. in Biology at Caltech in 1995 and obtained his M.D.-Ph.D. from UCLA in 2003. After internship also at UCLA, he went on to radiology residency and neuroradiology fellowship both at Stanford. He has been faculty in Stanford Neuroradiology since 2010. He spearheads many initiatives in advanced clinical imaging at Stanford, including clinical fMRI and DTI. Simultaneously, he runs a lab with the goal of discovering new imaging abnormalities in neurodegenerative disorders, with a focus on detailed microcircuitry in regions such as the hippocampal formation using advanced, multi-modal in vivo and ex vivo methods, with applications to neurodegenerative disorders such as Alzheimer’s disease and mild traumatic brain injury.

  • Jamie Zeitzer, PhD

    Jamie Zeitzer, PhD

    Professor (Research) of Psychiatry and Behavioral Sciences (Sleep Medicine)

    Current Research and Scholarly InterestsDr. Zeitzer is a circadian physiologist specializing in the understanding of the impact of light on circadian rhythms and other aspects of non-image forming light perception.
    He examines the manner in which humans respond to light and ways to manipulate this responsiveness, with direct application to jet lag, shift work, and altered sleep timing in teens. Dr. Zeitzer has also pioneered the use of actigraphy in the determination of epiphenomenal markers of psychiatric disorders.

  • Tian Yi Zhang, MD, PhD

    Tian Yi Zhang, MD, PhD

    Assistant Professor of Medicine (Hematology)

    BioDr. Zhang is a board-certified hematologist. She is also an assistant professor of hematology at Stanford University School of Medicine. In addition to her medical degree, she holds a PhD in cellular and molecular immunology.

    In her clinical practice, she treats patients with all forms of hematological malignancies, offering specialized expertise in acute myeloid leukemia, including therapy-resistant cases. For each patient, she develops a personalized care plan encompassing novel treatment options.

    Her research activities include conducting early phase clinical trials, investigator initiated clinical trials (IITs), studying the immune repertoire in patients with myeloid malignancies, and exploring cholesterol metabolic dependencies of acute myeloid leukemia (AML).

    She was the recipient of an A.P. Giannini Foundation fellowship award, which supports innovative research. The award helped fund Dr. Zhang’s study of how AML cells interact with other cells in bone marrow. A significant finding confirmed that AML cells secrete a protein that suppresses the production of red blood cells, the same protein that causes inflammation in disorders such as rheumatoid arthritis and Crohn’s disease.

    Her many other honors include the National Cancer Institute Career Development (K08) Award, the American Society of Hematology (ASH) Research Training Award for Fellows, Stanford Cancer Institute - American Cancer Society (SCI-ACS) Pilot Grant and Best ASH Abstract Award two years in a row. She also has earned recognition from the National Institutes of Health and American College of Physicians.

    She has published her research findings on topics such as advanced therapy for high-risk myelodysplastic syndromes and reversal of bone marrow failure induced by AML. Her work has appeared in Leukemia & Lymphoma, Science Translational Medicine, Cancer Research, the Journal of Clinical Investigation, Journal of Immunology, and elsewhere.

    Dr. Zhang is a member of the American Association of Cancer Research and American Society of Hematology. She advises and mentors Stanford medical students, residents and fellows. She delivers invited lectures to faculty and fellows. In addition, she has been an invited speaker on the topic of acute myeloid leukemia at the Association of Northern California Oncologists Update on Hematological Malignancies.